摘要
目的:观察都梁软胶囊治疗脑动脉硬化眩晕症的临床效果。方法:将本院120例脑动脉硬化患者随机分为治疗组(80例,口服都梁软胶囊1.62 g,tid)和对照组(40例,口服氢化麦角碱1.00 mg,tid)。治疗后,观察2组患者疗效、血液流变学指标及不良反应发生情况。结果:对照组与治疗组总有效率比较,差异有统计学意义(77.50%vs.90.00%,P<0.05);2组血液流变学指标比较,差异均有统计学意义(P<0.05);治疗组不良反应发生率明显低于对照组(P<0.05)。结论:都梁软胶囊治疗脑动脉硬化眩晕症疗效显著,且不良反应轻微。
OBJECTIVE： To observe the clinical efficacy of duliang soft capsule in the treatment of cerebral arteriosclerosis ver- tigo. METHODS： 120 cases of cerebral arteriosclerosis patients in our hospital were randomly divided into 2 groups. The treatment group was treated with duliang soft capsule（80 cases, 1.62 g,tid）, while control group was hyderginum（40 cases, 1.00 mg, tid）. After treatment, the efficacy, the effects of therapeutic regimen on hemorheology and ADRs were recorded and comparied. RE- SULTS： After treatment, the total efficacy of treatment group was better than control group（77.50% vs. 90.00% ,P〈0.05）. The the effects of therapeutic regimen on hemorheology was also better （P〈 0.05）. Compared with control group, the ADRs were low in treatment group（P〈0.05）. CONCLUSION： Duliang soft capsule in the treatment of cerebral arteriosclerosis vertigo has good ef- fect, and low ADRs.
出处
《中国药房》
CAS
CSCD
北大核心
2011年第28期2627-2628,共2页
China Pharmacy
关键词
脑动脉硬化眩晕症
脑梗死
都梁软胶囊
cerebral arteriosclerosis vertigo
Cerebral infarction
Duliang soft capsule
